Life science news 25 May 2026: Lilly's retatrutide delivers bariatric-surgery-level weight loss in Phase 3, two landmark FDA approvals reshape oncology and hepatology, and a UK biotech targets the global AMR crisis. The week of 17 to 24 May 2026 delivered a dense...
Fixing the Wrong Problem: How Healthcare Misdiagnoses its Workforce Crisis
The healthcare sector has a burnout problem it keeps trying to solve with the wrong tools. Across Australia and globally, rates of psychological distress, absenteeism and early career exit among healthcare workers have reached levels that can no longer be attributed...
Burnout in the Helping Profession: Why Healthcare Keeps Getting it Wrong
Across the life sciences sector, a quiet crisis is unfolding. Researchers, clinicians, nurses, and social workers describe feeling trapped in a cycle with no exit: outwardly productive, inwardly depleted. Burnout is not a new phenomenon, but the life sciences...
Weekly News Roundup | 18 May 2026
Life science news 18 May 2026: FDA leadership turmoil, a landmark Alzheimer's breakthrough and a $15 billion China licensing deal define a historic week for the global industry. The week of 10 to 17 May 2026 delivered a concentration of high-impact events across...
Weekly News Roundup | 11 May 2026
Life science news 11 May 2026: M&A momentum, artificial intelligence diagnostics and a record week for deal-making define an active seven days for the global life science industry. The week of 4 to 10 May 2026 produced a dense cluster of major acquisitions, a...
GSK Secures $1bn Rights to SiranBio siRNA Therapy
GSK has entered into an exclusive licensing agreement with Chinese biotech Suzhou Siran Biotechnology (SiranBio), securing global rights to the company's early-stage small interfering RNA (siRNA) therapy, SA030, in a deal worth up to $1.005 billion in potential...
Weekly News Roundup | 20 April 2026
Life science news 20 April 2026: A landmark pancreatic cancer breakthrough, record-breaking biotech IPO, major UK investment announcements and a surge in FDA approvals define a momentous week for the global life science industry. Revolution Medicines reported on 13...
Strait of Hormuz Closure: The Threat to Global Medicine Supplies
When US and Israeli military operations against Iran began on 28 February 2026, the consequences for global energy markets were immediate and predictable. What was less widely anticipated was the scale of the disruption now rippling through the life sciences sector....
UK Government’s LSLIP: A New Era for British Life Science
UK Government's Life Sciences Large Investment Portfolio: A New Era for British Life Science The United Kingdom's life sciences sector received a significant policy boost on 14 April 2026 when the government formally announced the Life Sciences Large Investment...
The UK Spine Crisis: Beyond Posture to a Future of Regenerative Care
The UK is currently navigating a silent epidemic that threatens not only our collective physical well-being but also our national productivity and the long-term sustainability of our healthcare infrastructure. Musculoskeletal (MSK) conditions now impact nearly one in...
Weekly News Roundup | 13 April 2026
Life science news 13 April 2026: A record-breaking wave of M&A, an escalating GLP-1 pricing war and major FDA approvals define a landmark week for the global life science industry. Gilead Sciences announced on 7 April its acquisition of Munich-based antibody-drug...
Weekly News Roundup | 6 April 2026
Life science news 6 April 2026: A landmark obesity pill approval, 100% pharma tariffs and a record $6.3 billion life sciences fund headline a transformative week for the global pharmaceutical industry. The FDA approved Eli Lilly's once-daily obesity pill Foundayo...
Python Blood Molecule Opens Door to New Obesity Treatments
Scientists studying the extraordinary metabolism of Burmese pythons have identified a python blood molecule that dramatically suppresses appetite in obese mice, raising the prospect of a new class of weight loss therapies that could avoid some of the side effects...
Weekly News Roundup | 30 March 2026
Life science news 30 March 2026: Three blockbuster deals, two FDA accelerated approvals and intensifying GLP-1 competition headline a busy week for pharma and biotech. Merck agreed on 25 March to acquire Terns Pharmaceuticals for $6.7 billion, gaining access to...
Weekly News Roundup | 23 March 2026
Your essential life science news 23 March 2026 digest: the past week’s biggest stories in pharma, biotech and healthcare. The FDA approved Johnson and Johnson's once-daily psoriasis pill ICOTYDE (icotrokinra) on 18 March, making it the world's first oral peptide to...
Power Outages as a Clinical Risk Multiplier in Healthcare
Electricity as a Hidden Dependency in Healthcare Reliable electricity is a foundational requirement for modern healthcare systems. From acute hospital care to long-term residential facilities and home-based treatment, uninterrupted power underpins virtually every...
I’m a Menopause Doctor – Here’s the Real Problem with Fezolinetant
With news of a HRT alternative for women struggling with hot flushes now available on the NHS, Dr Louise Newson explains why when it comes to Fezolinetant, women need to proceed with caution. UK medicines regulator NICE reported that they're in the final stages of...
Microplastics From Food Packaging Linked to Liver Damage, New Study Finds
New research has found that microplastics from food packaging could cause damage to the normal function and health of the liver. Microplastics - small fragments less than 5mm in size - are already known to be widespread in the food and drink that we consume. It is...







